Reduced expression of endogenous secretory receptor for advanced glycation endproducts in hippocampal neurons of Alzheimer's disease brains

Archives of Histology and Cytology

Volumn 70, Issue 5, 2007, Pages 279-290

  Nozaki, Ichiro ^a   Watanabe, Takuo ^a   Kawaguchi, Makoto ^b   Akatsu, Hiroyasu ^c   Tsuneyama, Koichi ^d   Yamamoto, Yasuhiko ^a   Ohe, Kazuyo ^a   Yonekura, Hideto ^e   Yamada, Masahito ^a   Yamamoto, Hiroshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b Niigata Rousai Hospital   (Japan)

^c Fukushimura Hospital   (Japan)

^d UNIVERSITY OF TOYAMA   (Japan)

^e KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR;

AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DENTATE NUCLEUS; FEMALE; GRANULE CELL; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; NERVE CELL; PATHOLOGY; PROTEIN EXPRESSION; PYRAMIDAL NERVE CELL; QUANTITATIVE ANALYSIS; WESTERN BLOTTING;

AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; RECEPTORS, IMMUNOLOGIC;

EID: 42649088066     PISSN: 09149465     EISSN: 13491717     Source Type: Journal    
DOI: 10.1679/aohc.70.279     Document Type: Article

References (29)

1. Akatsu H, Takahashi M, Matsukawa N, Ishikawa Y, Kondo N, Sato T, Nakazawa H, Yamada T, Okada H, Yamamoto T, Kosaka K: Subtype analysis of neuropathologically diagnosed patients in a Japanese geriatric hospital. J Neurol Sci196: 63-69 (2002).
2. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T: Inflammation and Alzheimer's disease. Neurobiol Aging 21: 383-421 (2000).
3. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82: 239-259 (1991).
4. Cheng C, Tsuneyama K, Kominami R, Shinohara H, Sakurai S, Yonekura H, Watanabe T, Takano Y, Yamamoto H, Yamamoto Y: Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 18: 1385-1396 (2005).
5. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B: RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9: 907-913 (2003).
6. Donahue JE, Flaherty SL, Johanson CE, Duncan JA 3rd, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG: RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol 112: 405-415 (2006).
7. Hanford LE, Enghild JJ, Valnickova Z, Petersen SV, Schaefer LM, Schaefer TM, Reinhart TA, Oury TD: Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J Biol Chem 279: 50019-50024 (2004).
8. Harashima A, Yamamoto Y, Cheng C, Tsuneyama K, Myint KM, Takeuchi A, Yoshimura K, Li H, Watanabe T, Takasawa S, Okamoto H, Yonekura H, Yamamoto H: Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression. Biochem J 396: 109-115 (2006).
9. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM: RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97: 889-901 (1999).
10. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen JX, Nagashima M, Lundh ER, Vijay S, Nitecki D, Morser J, Stern D, Schmidt AM: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. J Biol Chem 270: 25752-25761 (1995).
11. Huttunen HJ, Fages C, Rauvala H: Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF- κB require the cytoplasmic domain of the receptor but different downstream signaling pathways. J Biol Chem 274: 19919-19924 (1999).
12. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, Emoto M, Shoji T, Tamei H, Matsuki H, Sakurai S, Yamamoto Y, Yonekura H, Watanabe T, Yamamoto H, Nishizawa Y: Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vase Biol 25: 2587-2593 (2005).
13. Kumada T, Tsuneyama K, Hatta H, Ishizawa S, Takano Y: Improved 1-h rapid immunostaining method using intermittent microwave irradiation: practicability based on 5 years application in Toyama Medical and Pharmaceutical University Hospital. Mod Pathol 17: 1141-1149 (2004).
14. Lander HM, Tauras JM, Ogiste JS, Hori O, Moss RA, Schmidt AM: Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 272: 17810-17814 (1997).
15. Lue LF, Walker DG, Rogers J: Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging 22: 945-956 (2001).
16. Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, Yan SD, Stern D, Schmidt AM, Frangione, B, Zlokovic BV: Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest 102: 734-743 (1998).
17. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L: The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486 (1991).
18. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ Jr, Chow WS, Stern D, Schmidt AM: Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4: 1025-1031 (1998).
19. Renard C, Chappey O, Wautier MP, Nagashima M, Lundh E, Morser J, Zhao L, Schmidt AM, Scherrmann JM, Wautier JL: Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol 52: 54-62 (1997).
20. Sakurai S, Yamamoto Y, Tamei H, Matsuki H, Obata KI, Hui L, Miura J, Osawa M, Uchigata Y, Iwamoto Y, Watanabe T, Yonekura H, Yamamoto H: Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract 73: 158-165 (2006).
21. Sato T, Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M: Toxic advanced glycation end products (TAGE) theory in Alzheimer's disease. Am J Alzheimers Dis Other Demen 21: 197-208 (2006).
22. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, Wang F, Pan YCE, Tsang TC, Stern D: Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267: 14987-14997 (1992).
23. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D: Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions Arterioscler Thromb 14: 1521-1528 (1994).
24. Sousa MM, Yan SD, Stern D, Saraiva MJ: Interaction of the receptor for advanced glycation end products (RAGE) with transthyretin triggers nuclear transcription factor κ B (NF- κ B) activation. Lab Invest 80: 1101-1110 (2000).
25. Stren DM, Schmidt AM, Yan SD, Yan SF : Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes. Ageing Res Rev 1: 1-15 (2002).
26. West MJ, Kawas CH, Stewart WF, Rudow GL, Troncoso JC: Hippocampal neurons in pre-clinical Alzheimer's disease. Neurobiol Aging 25: 1205-1212 (2004).
27. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM: RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691 (1996).
28. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin Md J, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H: Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370: 1097-1109 (2003).
29. Yonekura H, Yamamoto Y, Sakurai S, Watanabe T, Yamamoto H: Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J Pharmacol Sci 97: 305-311 (2005).